Danaher Corporation (DHR) reported third-quarter results on October 21, 2026, with adjusted earnings per share up 11.5% to $2.11 and revenue up 8.5% to $6.6 billion. The stock has since pushed to about $235.50, a new recent high close. The balance of evidence leans positive with high conviction, because the daily and weekly trends agree and DHR is outrunning both the S&P 500 and healthcare. The weak spot is the breakout math, which falls short of 3 to 1.
Why it matters
The quarter was clean. Per the PR Newswire release, net earnings were $1.2 billion, or $1.71 per diluted share, up 34.5% from a year earlier. Adjusted earnings per share grew faster than revenue, 11.5% against 8.5%. The SEC 8-K filing adds the figure that shows underlying demand: core revenue excluding respiratory rose 5.5%.
Most of this was already in the price. DHR went into the report up 6.5% over one month and 28% over six months, so the report confirmed a rising stock rather than resetting one. Today the shares are up 0.7% at $235.50 while the S&P 500 fell 0.97%, an orderly gain rather than a gap. Volume is 78.4% below its 20-day average, but the data was taken early in the session, so that number will fill in. The news feed gives no consensus figures, so it cannot say whether the quarter beat expectations.
Over the last five days the stock gained 1.7%, the S&P 500 0.45% and the healthcare sector ETF (XLV) 2.9%. The market explains little of that. The sector explains most of it, and DHR lagged XLV by about 1.1 percentage points. Over 50 days the picture is the reverse: DHR leads the S&P 500 by 9.5 points and XLV by 3.7. The week's move was DHR riding a healthcare advance, not leading it. The Masimo FDA clearance on October 17, 2026 is a product item and does not by itself explain any of this.
The news feed carries no articles arguing the case for or against DHR, so the debate has to be read from the numbers. The constructive side points to earnings growing faster than sales and to 22 analysts rating the stock a strong buy, with a mean price target of $247.18. The cautious side notes that the price is already within 4.7% of that mean, that the lowest target, $200, sits below the current price, and that the spread to the highest, $310, shows how far apart analysts are on what the business is worth. The stock is not cheap against its own consensus, but it is not stretched past the analyst range either.
What the evidence says
On the long term, the thesis is intact. The price is above its 40-week average, the 50-day average at $215.71 sits above the 200-day at $201.25, and the stock is 45% above its 52-week low of $161.91. It is in an advance that has run most of the way back to the 52-week high of $242.05, just 2.7% away. The year-to-date gain of 2.9% is small only because the first part of the year was spent lower. The 14-day RSI of 71.8 says the recent leg has been fast.
For the next 2 to 6 weeks, the balance of evidence leans positive, and conviction is high at 3 of 4 points. The daily trend runs with the weekly uptrend. DHR leads the S&P 500 over 50 days by 9.5%, and it leads XLV by 3.7%. Those are the three supports behind the reading. Conviction is one point short of full strength because the fourth test did not line up.
The strongest case against is about price, not trend. An RSI near 72 and light early volume describe a stock that has run ahead of its participation. The stock also trailed its sector by 1.1 points this week. And the upside math is thin: the first target is only 0.4 times the risk. None of this tips the balance. Stretched readings say how far the price has travelled, not that the trend has broken, and the trend and relative-strength evidence has not weakened. It is a reason conviction is not higher.
Levels that matter
The structure holds above $225, a round number and the first place a pullback would show damage if it broke. Below it sit the 50-day average at $215.71 and, further down, the swing zone at $209.26. That is where the trend would end, because it marks the last area where buyers have defended the advance. The 200-day average at $201.25 and the round $200 sit underneath as a second floor.
The breakout level is a daily close above $242.05, the 52-week high, on volume above its 20-day average. From there the first target is $250 and the second is $275. A breakout would be wrong below $223.25, which is $225 less a quarter of the 14-day ATR of $6.99. The reward-to-risk is 0.4 to 1 at $250 and 1.8 to 1 at $275. That does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target far beyond $275, or a stop much closer to the entry, to change that.
What would change the picture
A weekly close below $209.26, the swing zone, would end the uptrend as the evidence now describes it. The non-price fact that would most likely cause it is a slowdown in underlying demand: core revenue growth excluding respiratory falling back from this quarter's 5.5%, or an outlook cut that points the same way. Either would undercut the earnings-growth story that supports the current price.
What to watch
- Next earnings: the date is not in the data, since the quarter just reported on October 21, 2026. The one number that matters is core revenue growth excluding respiratory, against 5.5% this time.
- Sector events: peers reporting before DHR's next results, such as Thermo Fisher, named in Benzinga's earnings-week list. XLV is up 5.9% over a month, so a sector pause would reach DHR first. The October 13, 2026 8-K on director or officer changes is also on file, though its details are not in the summary.
- Valuation: at about $235.50 the stock sits 4.7% below the $247.18 mean price target, inside a $200 to $310 analyst range.